| scholarly article | Q13442814 |
| P2093 | author name string | Charles W McMonnies | |
| P2860 | cites work | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. | Q52608828 |
| Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases. | Q52679059 | ||
| An overview on dry eye treatment: approaches for cyclosporin a delivery | Q57378877 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society | Q28067433 | ||
| Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation | Q34627019 | ||
| The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction | Q34769319 | ||
| Cyclosporine A delivery to the eye: A pharmaceutical challenge | Q35577456 | ||
| Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal gland | Q35684758 | ||
| Parsing interindividual drug variability: an emerging role for systems pharmacology | Q36417380 | ||
| Topical ophthalmic cyclosporine: pharmacology and clinical uses | Q37473764 | ||
| Cytokines and chemokines in immune-based ocular surface inflammation. | Q37755206 | ||
| Clinical Review: Topical Ophthalmic Use of Cyclosporin A | Q37782084 | ||
| Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis | Q38516740 | ||
| Lifitegrast for the treatment of dry eye disease in adults | Q38608475 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin | Q40213530 | ||
| Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children | Q41809327 | ||
| Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome | Q44006693 | ||
| A new approach for better comprehension of diseases of the ocular surface | Q44020701 | ||
| Paracellular permeability of corneal and conjunctival epithelia | Q46861464 | ||
| Update in Current Diagnostics and Therapeutics of Dry Eye Disease. | Q47424328 | ||
| Conjunctival Tear Layer Temperature, Evaporation, Hyperosmolarity, Inflammation, Hyperemia, Tissue Damage, and Symptoms: A Review of an Amplifying Cascade | Q47807844 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| Dry Eye Disease | Q61759579 | ||
| P304 | page(s) | 12 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Eye and vision (London, England) | Q27726793 |
| P1476 | title | Dry eye disease immune responses and topical therapy | |
| P478 | volume | 6 |
| Q89539996 | Aqueous deficiency is a contributor to evaporation-related dry eye disease | cites work | P2860 |
Search more.